190 related articles for article (PubMed ID: 34357770)
21. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC.
Barb AW; Leavy TM; Robins LI; Guan Z; Six DA; Zhou P; Hangauer MJ; Bertozzi CR; Raetz CR
Biochemistry; 2009 Apr; 48(14):3068-77. PubMed ID: 19256534
[TBL] [Abstract][Full Text] [Related]
22. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
Zhang J; Zhang L; Li X; Xu W
Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and dynamics of bacterial populations during postantibiotic effect determined by flow cytometry.
Gottfredsson M; Erlendsdóttir H; Sigfússon A; Gudmundsson S
Antimicrob Agents Chemother; 1998 May; 42(5):1005-11. PubMed ID: 9593117
[TBL] [Abstract][Full Text] [Related]
24. Molecular recognition by Escherichia coli UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase is modulated by bound metal ions.
Hernick M; Fierke CA
Biochemistry; 2006 Dec; 45(49):14573-81. PubMed ID: 17144651
[TBL] [Abstract][Full Text] [Related]
25. The postantibiotic effect induced by antimicrobial combinations.
Gudmundsson S; Erlendsdóttir H; Gottfredsson M; Gudmundsson A
Scand J Infect Dis Suppl; 1990; 74():80-93. PubMed ID: 2129068
[TBL] [Abstract][Full Text] [Related]
26. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
27. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.
Kalinin DV; Agoglitta O; Van de Vyver H; Melesina J; Wagner S; Riemann B; Schäfers M; Sippl W; Löffler B; Holl R
Bioorg Med Chem; 2019 May; 27(10):1997-2018. PubMed ID: 30954331
[TBL] [Abstract][Full Text] [Related]
28. 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors.
Zuo K; Liang L; Du W; Sun X; Liu W; Gou X; Wan H; Hu J
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481250
[TBL] [Abstract][Full Text] [Related]
29. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
Liu F; Ma S
Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
[TBL] [Abstract][Full Text] [Related]
30. Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Retain Activity against Multidrug-Resistant Pseudomonas aeruginosa
Moustafa DA; Wu AW; Zamora D; Daly SM; Sturge CR; Pybus C; Geller BL; Goldberg JB; Greenberg DE
mBio; 2021 Jan; 12(1):. PubMed ID: 33436433
[TBL] [Abstract][Full Text] [Related]
31. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
32. Cloning, expression, and purification of UDP-3-O-acyl-GlcNAc deacetylase from Pseudomonas aeruginosa: a metalloamidase of the lipid A biosynthesis pathway.
Hyland SA; Eveland SS; Anderson MS
J Bacteriol; 1997 Mar; 179(6):2029-37. PubMed ID: 9068651
[TBL] [Abstract][Full Text] [Related]
33. Postantibiotic effect, and postantibiotic effect of subinhibitory concentrations, of sparfloxacin on gram-negative bacteria.
Odenholt-Tornqvist I; Bengtsson S
Chemotherapy; 1994; 40(1):30-6. PubMed ID: 8306813
[TBL] [Abstract][Full Text] [Related]
34. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.
Odenholt-Tornqvist I
J Antimicrob Chemother; 1993 Jun; 31(6):881-92. PubMed ID: 8360126
[TBL] [Abstract][Full Text] [Related]
35. Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method.
Isaksson B; Nilsson L; Maller R; Sörén L
J Antimicrob Chemother; 1988 Jul; 22(1):23-33. PubMed ID: 3139614
[TBL] [Abstract][Full Text] [Related]
36. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
[TBL] [Abstract][Full Text] [Related]
37. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
Cuny GD
Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the antibacterial target UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC): isoxazoline zinc amidase inhibitors bearing diverse metal binding groups.
Pirrung MC; Tumey LN; Raetz CR; Jackman JE; Snehalatha K; McClerren AL; Fierke CA; Gantt SL; Rusche KM
J Med Chem; 2002 Sep; 45(19):4359-70. PubMed ID: 12213077
[TBL] [Abstract][Full Text] [Related]
39. Impact of pH and cationic supplementation on in vitro postantibiotic effect.
Gudmundsson A; Erlendsdottir H; Gottfredsson M; Gudmundsson S
Antimicrob Agents Chemother; 1991 Dec; 35(12):2617-24. PubMed ID: 1810197
[TBL] [Abstract][Full Text] [Related]
40. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H
Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
